- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Device start-up markets new glaucoma therapy
Boston—After nearly 5 years of research and product development for glaucoma treatment systems, SOLX has launched commercial operations.
Boston-After nearly 5 years of research and product development for glaucoma treatment systems, SOLX has launched commercial operations.
A product of the Boston University Photonics Center's Business Acceleration Program, the company created the DeepLight Glaucoma Treatment System for decreasing IOP. The system combines a titanium sapphire laser and a photo-modulated gold shunt to reduce or eliminate the need for glaucoma medications. The laser is designed to minimize thermal damage to the trabecular meshwork, and the treatment can be performed annually as an alternative to daily drops, according to the company.
Some 50 patients worldwide have been treated by the system, and doctors from six nations were trained on the technology in February in Madrid.
